Pliant Therapeutics, Inc. (NASDAQ:PLRX) Insider Hans Hull Sells 15,936 Shares of Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) insider Hans Hull sold 15,936 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the sale, the insider now owns 211,558 shares of the company’s stock, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Pliant Therapeutics Trading Down 1.4 %

Shares of PLRX stock opened at $10.92 on Thursday. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $13.24 and a 200-day moving average of $13.08. Pliant Therapeutics, Inc. has a one year low of $10.22 and a one year high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.04. On average, equities research analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.50.

Institutional Trading of Pliant Therapeutics

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in Pliant Therapeutics by 27.2% in the 4th quarter. SG Americas Securities LLC now owns 30,729 shares of the company’s stock valued at $405,000 after purchasing an additional 6,579 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Pliant Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 108,608 shares of the company’s stock worth $1,430,000 after buying an additional 16,634 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Pliant Therapeutics by 4.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 95,801 shares of the company’s stock worth $1,262,000 after buying an additional 3,822 shares during the last quarter. Exome Asset Management LLC grew its position in Pliant Therapeutics by 20.6% during the third quarter. Exome Asset Management LLC now owns 149,600 shares of the company’s stock valued at $1,677,000 after buying an additional 25,600 shares during the period. Finally, Franklin Resources Inc. increased its holdings in Pliant Therapeutics by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock worth $11,657,000 after buying an additional 14,913 shares during the last quarter. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.